Navigation Links
Anthony A. Charity Joins Tunnell Consulting
Date:12/10/2013

King of Prussia, PA (PRWEB) December 10, 2013

Tunnell Consulting, Inc. today announced that Anthony A. Charity, who served in the U.S. Food and Drug Administration (FDA) for more than twenty years, has joined the firm as a Managing Consultant, Quality and Compliance.

“Anthony Charity’s experience at the FDA enables him to provide our life sciences clients with invaluable help in understanding good manufacturing practices, preparing for inspections, and mitigating compliance risks,” said Philippe Cini, Ph.D., Group Vice President. “His expertise complements Tunnell’s longstanding strengths in quality and compliance, areas in which excellence is absolutely critical for pharmaceutical companies.”

Prior to joining Tunnell, Mr. Charity served as FDA Branch Chief for the Dedicated Drug Cadre Division of Medical Products and Tobacco Inspection, Rockville, MD, where he supervised drug investigators who inspected the foreign manufacturing operations of firms who market pharmaceutical products in the U.S.

“I am delighted to join Tunnell’s Quality and Compliance practice, with its long track record of success, its exclusive focus on the pharmaceutical industry, and its proven methodologies for addressing quality and compliance,” said Mr. Charity. “In a regulatory environment that is becoming increasingly science-driven, the firm offers to clients a breadth and depth of resources that is hard to match.”

Prior to his role as a Branch Chief, Mr. Charity served as a Compliance Officer for the FDA’s Center for Drug Evaluation and Research (CDER), Division of Manufacturing and Product Quality. At CDER, he reviewed proposed regulatory actions for conclusiveness and acceptability of evidence; nature and extent of deviations from current good manufacturing practices (cGMPs), and appropriate regulatory action strategy. He is expert at identifying and evaluating cGMP problems in the manufacture and control of active pharmaceutical ingredients (APIs) and intermediates and their impact on the quality of finished pharmaceuticals.

He also authored the “Active Pharmaceutical Ingredient Process Inspection Compliance Program Guidance Manual 7356.002F,” a comprehensive cGMP inspection guide for determining whether a manufacturer of APIs is operating in a state of control.

He began his career with the FDA as the Consumer Safety Officer, U.S. Custom House, Philadelphia, PA, where he conducted inspections in industries that were regulated by the FDA, primarily in the pharmaceutical, bioresearch monitoring and good laboratory practices areas.

Mr. Charity received his B.A. in Chemistry from Cheyney State University, Cheyney, PA.

About Tunnell Consulting
Founded in 1962 and serving many of the world’s leading life sciences firms and government agencies, Tunnell Consulting, Inc. integrates strategic, technical, process, and organizational skills to design and implement sustainable solutions that exactly meet client needs. With deep industry knowledge, extensive scientific credentials, and superior measurable results, we consistently boost the operating performance of each unique client we serve.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11401819.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dwaine Rieves, MD, Anthony Di Santo, PhD and Joachim Vollmar, MSc Join NDA Partners as Premier Expert Consultants
2. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
3. ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21
4. Vet-Stem, Inc. Founder, Robert Harman, DVM, Invited as Inspirational Speaker for the 6th Annual After the Finish Line Charity Dinner
5. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
6. Robert Farrell Joins Bionovos Board of Directors
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
9. First Choice Rehabilitation Specialists Joins Select Medical
10. Excel Life Sciences Joins DATATRAKs Connect Partner Program
11. Marina Biotech, Inc. Joins OTCQX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... ... 2017 , ... On Tuesday, October 24th, ABC² (Accelerate Brain ... adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. Brian ... to the public, but registration is required. , WHAT: ABC² Brain Cancer ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):